abnormalities

Nicotinamide riboside increases NAD[+] levels and activates SIRT1 and SIRT3, culminating in enhanced oxidative metabolism and protection against high fat diet-induced metabolic abnormalities.

Nicotinamide riboside chloride, also known as NR and SRT647, is a pyridine-nucleoside form of vitamin B3 that functions as a precursor to nicotinamide adenine dinucleotide or NAD+.

NKL 22 (Histone Deacetylase Inhibitor IV) is an effective Histone Deacetylase Inhibitor.

BO-264 is a highly potent and orally active inhibitor of transforming acidic coiled-coil 3 (TACC3) with an IC50 of 188 nM and a Kd of 1.5 nM.

NSC 617145 (NSC617145) is an inhibitor of WRN helicase that inhibits the ATPase, but not exonuclease, activity of WRN helicase in a concentration-dependent manner.

McN5691 (RWJ26240) is a voltage-dependent calcium channel blocker with antihypertensive activity that can be used in the study of diseases caused by vascular smooth muscle abnormalities.

MK-0773 (PF-05314882) is a selective androgen receptor modulator that binds to AR (IC50: 6.6 nM) for the study of diseases caused by endocrine abnormalities.

PAOPA belongs to natural product derivatives and serves as an allosteric modulator of the dopamine D2 receptor, possessing the characteristic of promoting binding between high-affinity D2 receptors and agonists. This compound finds application in preclinical studies for schizophrenia and extrapyramidal dysfunction, effectively alleviating behavioral and biochemical abnormalities in rodent models.

Osemozotan HCl (Osemozotan hydrochloride) is a novel and selective 5-HT1A receptor agonist that reduces methamphetamine-induced c-Fos expression in the medial prefrontal cortex and striatum.Osemozotan HCl is used in the study of mechanical abnormalities of pain and depression.

IMPDH2-IN-2 is a potent inhibitor of inosine 5'-monophosphate dehydrogenase (IMPDH) (Ki,app: 14 μM) and a potential anti-tuberculosis agent, exhibiting moderate antibacterial effects with MIC values of 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively.

Dantrolene sodium (Dantrolene sodium salt) is a skeletal muscle relaxant and can interfere with excitation-contraction coupling in the muscle fiber. It is used for the treatment of spasticity and other neuromuscular abnormalities. Its mechanism of action is may not central, but dantrolene is usually grouped with the central muscle relaxants.

Ilepatril TFA is a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), exhibiting physiological effects such as enhanced natriuresis and vasodilation. In animal studies and early clinical trials, Ilepatril TFA has demonstrated the ability to improve insulin sensitivity and metabolic abnormalities, suggesting its potential value in the treatment of cardiovascular and metabolic diseases.

4-Deoxypyridoxine (4-DPD) is a vitamin B6 antimetabolite with diverse biological activities. It inhibits transport of pyridoxine , pyridoxal, and pyridoxamine in and reduces growth of S. carlsbergensis cells. 4-DPD inhibits sphingosine-1-phosphate (S1P) lyase and reduces cyclic stretch-induced apoptosis in alveolar epithelial MLE-12 cells. 4-DPD (5 mg, i.p.) reduces lysyl oxidase activity by 26% and reduces collagen and elastin crosslinking, resulting in limb abnormalities in chick embryos. It decreases latency to first seizure in mice (ED50 = 1 mmol/kg) and increases the occurrence and duration of myoclonic responses in baboons with photosensitive epilepsy. 4-DPD reduces TNF-α and IL-6 production in mice infected with T. spiralis.

3-Amino-2-methylpropanoic acid (α-Methyl-β-alanine) is the product from the conversion of N-carbamyl-beta-aminoisobutyric acid by the enzyme Beta-ureidopropionase (EC 3.5.1.6), the last step in pyrimidine degradation. Beta-ureidopropionase deficiency is an inborn error of pyrimidine degradation associated with neurological abnormalities.

Carbonic anhydrase inhibitor 6 is a potent human carbonic anhydrase (hCA) inhibitor that inhibits hCA IX, hCA II, hCA XII, and hCA I. It is used in the study of diseases caused by abnormalities in carbonic anhydrase.

TR antagonist 1 is a highly potent thyroid hormone receptor (TR) antagonist (IC50 of 36 and 22 nM for TRα and TRβ, respectively) that can be used to study diseases caused by endocrine abnormalities.

DNMT1/HDAC-IN-1 (compound (R)-23a), a potent dual inhibitor targeting both DNMT1 and HDAC, exhibits impressive inhibitory effects specifically on HDAC1 (HDAC1:IC50=0.05 μM), a major HDAC isoform that interacts with DNMT1 across multiple protein complexes involved in the transcriptional silencing of TSGs. This compound has been shown to remodel the tumor immune microenvironment and induce tumor regression, effectively reversing cancer-specific epigenetic abnormalities.

TAS2940 is an irreversible pan-ERBB inhibitor with enhanced brain penetration, utilized for treating lung cancer brain metastases and glioblastomas with HER2/EGFR exon 20 insertions and EGFR abnormalities. In intracranial xenograft models of HER2/EGFR cancers, TAS2940 has demonstrated efficacy in improving survival rates in mice. Currently, TAS2940 is undergoing Phase I clinical trials to establish the maximum tolerated dose for solid tumors.

TU-100 is frequently used in the treatment of chronic gastrointestinal disorders, and it is commonly applied to alleviate symptoms such as abdominal pain, bloating, Crohn’s disease, irritable bowel syndrome, adhesive intestinal obstruction, and paralytic ileus. Additionally, TU-100 can improve gastrointestinal motility abnormalities in patients with grade B liver impairment after hepatectomy and reduce serum CRP levels.

AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. It exhibits strong DPPH radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies demonstrate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical parameters compared to controls, and no abnormalities in liver and kidney tissues. This compound shows potential for Alzheimer's disease research.

Ferumoxytol is an iron oxide nanoparticle with anti-leukemia properties, specifically against acute myeloid leukemia (AML) cells with low ferroportin (FPN) expression. By increasing intracellular iron levels, Ferumoxytol induces the Fenton reaction to produce reactive oxygen species (ROS), resulting in oxidative stress and ferroptosis. It selectively kills leukemia cells with low FPN expression while sparing normal cells, making it useful for studying leukemia targeting iron metabolism abnormalities.

TEAD1/3/4-IN-1 (compound 1) is an inhibitor of TEAD1/3/4 that suppresses YAP/TAZ-TEAD interactions. It exhibits antitumour activity against NF2-deficient NCI-H226 cells and may be employed in studies of cancer and diseases mediated by Hippo pathway abnormalities.

MAO-B-IN-44 (Compound 4n) is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 1.01 μM, demonstrating weak inhibition of MAO-A (IC50=14.4 μM). It reduces the degradation of neurotransmitters like dopamine and holds potential for research into neurodegenerative diseases such as Parkinson's disease, which are associated with MAO-B abnormalities.

3-Hydroxyvalproic acid (3-Hydroxy VPA) is a metabolite of valproic acid. It acts as a mild inhibitor of enzymes related to the mitochondrial β-oxidation pathway. This compound holds potential for research in disorders associated with abnormalities in valproic acid metabolism.